Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in Advanced Angiosarcoma
NCT04859465Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2021
- Primary completion
- May 2027
- Modality
- Polymer-based Nanoparticles, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel, pegylated liposomal doxorubicin in angiosarcoma, sponsored by Sun Yat-sen University. Started May 2021; status: recruiting.
02
Drugs
nab-paclitaxelpegylated liposomal doxorubicin
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT04859465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859465.